MTNB vs NAMSW

Matinas Biopharma Holdings, Inc vs NewAmsterdam Pharma Company N.V — Valuation Comparison 2026

MTNB

Pharmaceutical Preparations
Matinas Biopharma Holdings, Inc
Quality
4.0
out of 10
Value Trap
31
LOW
Price
$0.81
Last close
Models
7/13
Active
VS

NAMSW

Pharmaceutical Preparations
NewAmsterdam Pharma Company N.V
Quality
2.2
out of 10
Value Trap
Price
$25.00
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType MTNB Fair ValueMTNB Upside NAMSW Fair ValueNAMSW Upside
Bayesian DCF Intrinsic $0.42 -48.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.02 -97.2% $3.60 -83.1%
Dynamic NAV Asset-Based $3.08 +279.9% $6.79 -68.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MTNB vs NAMSW — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MTNB vs NAMSW — Which Stock Is More Undervalued?

MTNB scores higher with a 4.0/10 quality rating vs NAMSW's 2.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Matinas Biopharma Holdings, Inc (MTNB) and NewAmsterdam Pharma Company N.V (NAMSW) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MTNB currently trades at $0.81 with a QOC of 4.0/10, while NAMSW trades at $25.00 with a QOC of 2.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).